antileukotriene


Also found in: Wikipedia.

an·ti·leu·ko·tri·ene

(an'tē-lū'kō-trī'ēn),
A drug that prevents or alleviates bronchoconstriction in asthma by blocking the production or action of naturally occurring leukotrienes; may also be useful in psoriasis.

Leukotrienes are eicosanoids derived from arachidonic acid, which is present in cell membranes. The cysteinyl leukotrienes, which are elaborated by bronchopulmonary mast cells, eosinophils, and probably alveolar macrophages, have been shown to mediate bronchoconstriction induced by exercise, hyperventilation in cold air, aspirin, and inhaled allergens. They act by stimulating a specific receptor, known as cysteinyl leukotriene receptor type 1 (CysLT1). Antileukotrienes having clinical usefulness in asthma include zileuton, which inhibits 5-lipoxygenase, an enzyme critical in the biosynthesis of leukotrienes, and leukotriene receptor antagonists (cinalukast, montelukast, zarirlukast, and others). Antileukotrienes reverse bronchconstriction in asthma to a lesser degree than β2-adrenergic agonists, but their effects are additive to those of the latter agents. In chronic asthma, antileukotrienes improve peak flow and FEV1 and reduce the frequency and severity of acute asthmatic attacks, the need for β2-agonists, and the need for corticosteroid rescue. They are particularly effective in the prophylaxis of asthma induced by exercise and aspirin. In contrast, many people with allergic asthma show little or no response. Antileukotrienes are not indicated in the treatment of an acute asthmatic attack or in mild, intermittent asthma controlled adequately with occasional use of inhaled β2-agonists. They have not been recommended as a substitute for inhaled corticosteroids in prophylaxis of asthma. Antileukotrienes are administered orally or by inhalation. Both onset and waning of clinical effects are gradual. Side-effects are minimal, but drug interactions may occur because of interference with cytochrome P-450 enzymes. Rare transitory elevations of hepatic aminotransferase have been reported with some agents.

antileukotriene

Any of a class of agents that either interferes with leukotriene synthesis or antagonises leukotriene receptors, which are as effective as cromolyn or theophylline, and may reduce the amount of inhaled steroids needed to control inflammation.

Antileukotrienes 
LTD4 receptor antagonists (Zafirkulast-Accolate)
 
Pros
LTD4-induced bronchoconstriction, early and late responses, exercise challenge, cold-induced asthma, chronic asthma.
 
5-Lipoxygenase inhibitor (Zileutron-Zyflo)
 
Pros
Asthma induced by exercise, cold, aspirin, bronchial hyperresponsiveness.
 
FLAP inhibitors (5-lipoxygenase-activating protein inhibitor)

Pros
Early and late responses and cold-induced asthma.

antileukotriene

Any of a class of agents that either interfere with leukotriene synthesis or antagonize leukotriene receptors, which are as effective as cromolyn or theophylline, and may ↓ the amount of inhaled steroids needed to control inflammation See Asthma, Leukotrienes, Zafirlukast, Zileuton.
Antileukotrienes
LTD4 receptor antagonists
Zafirkulast-Accolate® Benefits LTD4-induced bronchoconstriction, early and late responses, exercise challenge, cold-induced asthma, chronic asthma
5-Lipoxygenase inhibitor
Zileutron-Zyflo®Benefits asthma induced by exercise, cold, aspirin, bronchial hyperresponsiveness
FLAP inhibitors
None are FDA-approved Benefits early and late responses and cold-induced asthma
.

an·ti·leu·ko·tri·ene

(an'tē-lū-ko-trī'ēn)
A drug that prevents or alleviates bronchoconstriction in asthma by blocking the production or action of naturally occurring leukotrienes; may also be useful in psoriasis.

an·ti·leu·ko·tri·ene

(an'tē-lū-ko-trī'ēn)
A drug that prevents or alleviates bronchoconstriction in asthma by blocking the production or action of naturally occurring leukotrienes; may also be useful in psoriasis.
References in periodicals archive ?
2) TABLE 2 Systemic Agents for Atopic Dermatitis in Ongoing or Completed Phase II Trials Drug Class Agent PDE-4 inhibitor (oral) Apremilast (oral) IL-13 inhibitors Lebrikizumab Tralokinumab IL-31 inhibitor Nemolizumab JAK inhibitors Tofacitinib Baricitinib Antileukotriene agents Q301 QAW039 Agents that target other pathways: H4 blockers Liver X receptor antagonists H=histamine; IL=interleukin; JAK=Janus kinase; PDE-4=phosphodiesterase type 4.
CLINICAL APPLICATION OF ANTILEUKOTRIENE DRUGS IN ASTHMA MANAGEMENT
Critical appraisal of antileukotriene use in asthma management.
Leukotriene modifiers: Leukotrienes are potent broncho-constrictors and antileukotriene drugs are either receptor antagonists or enzyme inhibitors.
14-16) Often, inhaled corticosteroids are used as combination therapy with a LABA or an antileukotriene agent (montelukast, zafirlukast; see below).
Antileukotriene drugs: clinical application, effectiveness and safety.
NO] for the two subjects taking antileukotriene medications alone was 21.
Antileukotriene agents, which interrupt the action of leukotrienes, have been found to be effective in the treatment of chronic asthma in adults.
Antileukotriene medications can help control asthma symptoms brought about by various triggers, including cold air.